Fundraising FoxOisin Biotechnologies
Seattle, US · Delaware corporation · 3 known investors
Find your way into Oisin Biotechnologies
Sign up to see every warm intro you have to Oisin Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oisin Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.
Founders & leadership
MS
SH
Stephen HilbertExecutive
JL
John LewisCSOJohn Lewis is an executive officer at Oisín Biotechnologies. His research background spans nanotechnology and imaging approaches for chronic disease, with prior focus on cancer metastasis and translating diagnostics and treatments to clinical applications.
Board
DG
David GobelBoard director
DQ
Danjuma QuarlessBoard director
Investors · 3
IKJ Capitallisted by IKJ CapitalPalo Alto
How we know: IKJ Capital's portfolio page · Not right? Tell us
Healthspan CapitalreportedOxford · $5K
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$18.4M disclosed across 4 rounds · 2017–2024
▶$5.4MraisedJul 2024 · 36 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJul 2024 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric GarciaExecutive Officer
- Matthew ScholzExecutive Officer, Director
- David GobelDirector
- Stephen HilbertExecutive Officer
- John LewisExecutive Officer
- Gary HudsonExecutive Officer, Director
- Danjuma QuarlessDirector
- Offering amount
- $17.9M
- Amount sold
- $5.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$475KraisedAug 2021 · 8 investors · OtherRule 506(b)
▶$475KraisedAug 2021 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric GarciaExecutive Officer
- Gary HudsonExecutive Officer, Director
- David GobelDirector
- Stephen HilbertExecutive Officer
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $475K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.5MraisedMay 2021 · 90 investors · OtherRule 506(b)
▶$9.5MraisedMay 2021 · 90 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- John LewisExecutive Officer
- Eric GarciaExecutive Officer
- Steve HilbertExecutive Officer
- Gary HudsonExecutive Officer, Director
- David GobelDirector
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $9.5M
- Amount sold
- $9.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedFeb 2020 · 48 investors · OtherRule 506(b)
▶$3MraisedFeb 2020 · 48 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Gary HudsonDirector
- David GobelDirector
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Oisin Biotechnologies went on to found or lead other companies.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ClementiaIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
Companies working in the same space as Oisin Biotechnologies.
Frequently asked questions
- What does Oisin Biotechnologies do?
- Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.
- Who founded Oisin Biotechnologies?
- Oisin Biotechnologies was founded by Matthew Scholz.
- Who are Oisin Biotechnologies's investors?
- Oisin Biotechnologies's investors include IKJ Capital, Methuselah Funds, Healthspan Capital.
- How much funding has Oisin Biotechnologies raised?
- Oisin Biotechnologies has disclosed $18.4M raised across 4 rounds.
- Where is Oisin Biotechnologies headquartered?
- Oisin Biotechnologies is headquartered in Seattle, US.